Amir T Fathi
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amir T Fathi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06707493 · Ivosidenib as Post-HSCT Maintenance for AMLMassachusetts General Hospital · recruiting · IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT) · principal investigator
- Ph2NCT04801797 · Venetoclax + Azacitidine vs. Induction Chemotherapy in AMLMassachusetts General Hospital · active not recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT03564821 · IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationMassachusetts General Hospital · completed · IDH1 Mutation Myeloid Neoplasms · principal investigator
- Ph1NCT03515512 · IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationMassachusetts General Hospital · completed · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia · principal investigator
- Ph1NCT02905994 · Volasertib Combined With Induction Chemotherapy in Acute Myeloid LeukemiaMassachusetts General Hospital · withdrawn · AML · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:29 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- 1,254 citationsRCR 40.6
- 1,249 citationsRCR 38.4
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.N Engl J Med · 20191,106 citationsRCR 41.3
- 318 citationsRCR 12.5
- 271 citationsRCR 9.4
- Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Biol Blood Marrow Transplant · 2014208 citationsRCR 6.1
- 198 citationsRCR 10.5
- 173 citationsRCR 8.4
- Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial.JAMA Oncol · 2021171 citationsRCR 13.1
- 160 citationsRCR 5.3